In the study of colon cancer, specific inhibitors of AKR1C1 and AKR1C3 or knockdowns of the genes in the resistant cells were used to resensitize the cells to cisplatin toxicity [25]. This evidence concerns the gene AKR1C3 and malignant colon neoplasm.